Table I.
Baseline clinical characteristics
| Redo
patients (n = 109) |
Control
group (n = 1258) |
p | |
|---|---|---|---|
| Age (years) | 56 ± 13 | 62 ± 10 | <0.01 |
| Female gender | 51 (46) | 425 (33) | 0.005 |
| HTN | 48 (45) | 705 (56) | 0.02 |
| DM | 39 (36) | 557 (44) | 0.07 |
| HL | 15 (14) | 283 (22) | 0.02 |
| Smoking | 20 (18) | 372 (29) | 0.009 |
| COPD | 13 (12) | 124 (10) | 0.29 |
| MI | 15 (13) | 418 (33) | <0.01 |
| Stroke/TIA | 8 (7.3) | 74 (6) | 0.32 |
| PVD | 4 (3.4) | 59 (4.7) | 0.42 |
| Renal failure | 6 (5.7) | 137 (10.9) | 0.05 |
| Infective endocarditis | 6 (5.5) | 12 (1) | 0.002 |
| AF | 30 (27.5) | 85 (6.8) | <0.01 |
| CHF | 3 (2.8) | 54 (4.3) | 0.31 |
| LVEF % | 60 (28–60) | 62 (20–65) | 0.54 |
| ≤30 | 6 (5.5) | 101 (8) | |
| 30.1–49 | 23 (21.1) | 302 (24.1) | |
| ≥50 | 80 (73.4) | 852 (67) | 0.44 |
| EuroSCORE | 6 (1–14) | 3 (0–14) | <0.01 |
| NYHA class III/IV | 44 (40) | 408 (32) | 0.05 |
| Status | 0.54 | ||
| Elective | 100 (93.5) | 1176 (93.6) | |
| Urgent/emergent | 7 (6.5) | 81 (6.4) | |
| Current operation | <0.01 | ||
| CABG | 53 (48.6) | 1119 (88.9) | |
| Aortic valve surgery | 32 (29.2) | 124 (9.8) | |
| Mitral valve surgery | 38 (34.8) | 154 (12.2) | |
| Tricuspid valve surgery | 17 (15.6) | 22 (1.7) | |
| Aortic surgery | 8 (7.3) | 50 (3.9) | |
| Previous operation | |||
| CABG | 63 (57.8) | ||
| Aortic valve | 21 (19.2) | ||
| Mitral valve | 33 (30.3) | ||
| Tricuspid valve | 3 (2.7) | ||
| Aortic surgery | 4 (3.6) | ||
| VSD closure | 2 (1.8) | ||
| Numbers are given as mean ± SD, median (minimum–maximum) or numbers (percentage). LVEF indicates left ventricular ejection fraction; CABG, coronary bypass grafting; PVD, peripheral vascular disease; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; VSD, ventricular septal defect | |||